Navigation Links
Flu virus wipes out immune system's first responders to establish infection
Date:10/20/2013

CAMBRIDGE, Mass. (October 20, 2013) -- Revealing influenza's truly insidious nature, Whitehead Institute scientists have discovered that the virus is able to infect its host by first killing off the cells of the immune system that are actually best equipped to neutralize the virus.

Confronted with a harmful virus, the immune system works to generate cells capable of producing antibodies perfectly suited to bind and disarm the hostile invader. These virus-specific B cells proliferate, secreting the antibodies that slow and eventually eradicate the virus. A population of these cells retains the information needed to neutralize the virus and takes up residence in the lung to ward off secondary infection from re-exposure to the virus via inhalation.

On the surface of these so-called memory B cells are high-affinity virus-specific receptors that bind virus particles to reduce viral spread. While such cells should serve at the body's first line of defense, it turns out that flu virus exploits the specificity of the cells' receptors, using them to gain entry, disrupt antibody production, and ultimately kill the cells. By dispatching its enemies in this fashion, the virus is able to replicate efficiently before the immune system can mount a second wave of defense. This seemingly counter-intuitive pathway to infection is described this week in the journal Nature.

"We can now add this to the growing list of ways that the flu virus has to establish infection," says Joseph Ashour, a co-author of the Nature paper and a postdoctoral researcher in the lab of Whitehead Member Hidde Ploegh.

"This is how the virus gains a foothold," adds Ploegh lab postdoc Stephanie Dougan, also a co-author of the study. "The virus targets memory cells in the lung, which allows infection to be established -- even if the immune system has seen this flu before."

Discovering this dynamic of the virus was no small task, in part because vi
'/>"/>

Contact: Matt Fearer
fearer@wi.mit.edu
617-452-4630
Whitehead Institute for Biomedical Research
Source:Eurekalert

Page: 1 2

Related biology news :

1. Studies reveal structure of EV71, a virus causing childhood illnesses
2. Discovery provides blueprint for new drugs that can inhibit hepatitis C virus
3. To drive infections, a hijacking virus mimics a cells signaling system
4. Scripps Research Institute scientists find promising vaccine targets on hepatitis C virus
5. Harmless human virus may be able to boost the effects of chemotherapy
6. Researchers identify Achilles heel of dengue virus, target for future vaccines
7. Recapitulation of the entire hepatitis C virus life in engineered mouse cell lines
8. BGI, GMU, Mass. Eye and Ear and OUHSC announce agreement to sequence 100 human adenoviruses
9. Berkeley Lab scientists generate electricity from viruses
10. Virus barcodes offer rapid detection of mutated strains
11. Army study: DNA vaccine and duck eggs protect against hantavirus disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... --- Do we think of nature as something that we ... need to "preserve?" Or do we think of ourselves as ... of nature, but what about a house? , The ... also reflected in our actions, our speech and in cultural ... the University of Washington, the American Indian Center of Chicago ...
(Date:9/30/2014)... The National Institutes of Health (NIH) awarded ... to develop an electrode array system that will ... works through unprecedented resolution and scale. , LLNL,s ... support President Obama,s BRAIN (Brain Research through ... effort to revolutionize our understanding of the human ...
(Date:9/30/2014)... New England Journal of Medicine reports positive results ... crizotinib against the subset of lung cancer marked by ... of 50 patients with advanced non-small cell lung cancer ... was 72 percent, with 3 complete responses and 33 ... takes for the disease to resume its growth after ...
Breaking Biology News(10 mins):The cultural side of science communication 2NIH taps lab to develop sophisticated electrode array system to monitor brain act 2NIH taps lab to develop sophisticated electrode array system to monitor brain act 3NEJM: Crizotinib effective in Phase 1 trial against ROS1 lung cancer 2
... (April 17, 2011) Michael Croft, Ph.D., a researcher ... has discovered a molecule,s previously unknown role as a ... making the molecule a promising therapeutic target for chronic ... lung conditions. A scientific paper on Dr. Croft,s ...
... WASHINGTON, D.C. April 14, 2011 ... Drug Administration (FDA) approved the NovoTTF-100A System (NovoTTF) ... multiforme (GBM) brain tumors, following tumor recurrence after ... an anti-mitotic, anti-cancer therapy as patients maintain their ...
... of the world,s two best-loved flavours and demand for it ... the global food industry could be more secure, thanks to ... is a compound that comes from the vanilla bean, the ... tropical, climbing vine originally cultivated by ancient Central American civilisations ...
Cached Biology News:La Jolla Institute identifies new therapeutic target for asthma, COPD and other lung disorders 2La Jolla Institute identifies new therapeutic target for asthma, COPD and other lung disorders 3FDA approves the NovoTTF-100A system for the treatment of patients with recurrent glioblastoma multiforme (GBM) brain tumors 2Preserving a world favorite flavour 2
(Date:10/1/2014)... 2014 Industry leaders from ... engage around the theme, ,Commercial Opportunities in the Era ... Elsevier , a world-leading provider of ... host a gathering of some of the industry,s most ... healthcare today and in the future. The ...
(Date:9/30/2014)... German . , ... demonstrated a new kind of building block for digital ... could be based on three-dimensional arrangements of nanometer-scale magnets ... the semiconductor industry CMOS fabrication of silicon chips ... at the University of Notre Dame are exploring "magnetic ...
(Date:9/30/2014)... Report Details Biosimilar drugs – ... Do you want to find sales potentials of ... for those biological drugs from 2014, helping you ... data, R&D trends, opportunities and selling prospects. In ... 2024 at overall world market, therapeutic class, molecule ...
(Date:9/30/2014)... Over the last decade, the laboratory ... R&D budgets and increased acceptance of new filtration technologies ... biotechnology industries are also catalyzing the growth of laboratory ... expected to grow at a strong CAGR during the ... worth $2,532.6 million by 2019. The market is mainly ...
Breaking Biology Technology:Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 2Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 3A new dimension for integrated circuits: 3-D nanomagnetic logic 2A new dimension for integrated circuits: 3-D nanomagnetic logic 3Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 2Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 3Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 4Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 5Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 2Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 3Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 4Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 5
... June 29 Sirnaomics, Inc. ( www.sirnaomics.com ) ... (Small Business Innovation Research) grants from National Cancer Institute ... Diseases  (NIAID), of National Institute of Health ... 2007, is dedicated to developing RNA interference (RNAi) therapeutics ...
... June 29, 2010 Cardio3,BioSciences, a leading Belgian biotechnology ... positive safety data and preliminary efficacy results from its,clinical trial of ... , , ... showed C-Cure to have a very good safety profile with no ...
... DALLAS, Texas , June 29, 2010 , ... - ReportsandReports Announces it Will Carry the Disease and Therapy,Review: Impetigo Market ... Browse the complete ... The Impetigo Disease and ...
Cached Biology Technology:Sirnaomics Receives Two SBIR Grants from NIH for Developing siRNA Therapeutics to Treat Glioblastoma and Influenza Infection 2Sirnaomics Receives Two SBIR Grants from NIH for Developing siRNA Therapeutics to Treat Glioblastoma and Influenza Infection 3Sirnaomics Receives Two SBIR Grants from NIH for Developing siRNA Therapeutics to Treat Glioblastoma and Influenza Infection 4Cardio3 BioSciences Reports Positive Three-Month Data From its Clinical Trial of C-Cure(R) in Heart Failure 2Cardio3 BioSciences Reports Positive Three-Month Data From its Clinical Trial of C-Cure(R) in Heart Failure 3Cardio3 BioSciences Reports Positive Three-Month Data From its Clinical Trial of C-Cure(R) in Heart Failure 4Cardio3 BioSciences Reports Positive Three-Month Data From its Clinical Trial of C-Cure(R) in Heart Failure 5Disease and Therapy Review: Impetigo Now Available at ReportsandReports 2Disease and Therapy Review: Impetigo Now Available at ReportsandReports 3Disease and Therapy Review: Impetigo Now Available at ReportsandReports 4Disease and Therapy Review: Impetigo Now Available at ReportsandReports 5
... CoA ligase (AMP forming), Acetate thiokinase ... content. Physical form: Lyophilized powder ... reduced glutathione Preparation Unit Definition: ... S-acetyl coenzyme A from acetate, ATP and ...
... The pYD1 Yeast Display Vector is specifically ... on the surface of Saccharomyces cerevisiae. Displayed ... to interact with known or putative ligands. ... which consists of two domains Aga1 and ...
... Mut S is a member of a class ... of the DNA sequence. Mut S plays an ... DNA ,replication, in transcription-coupled nucleotide excision repair and ... bacteria. Mut S binds to DNA specifically at ...
15(S)-HEDE is produced from 11Z,14Z-eicosadienoic acid by 15-LO. 15(S)-HEDE is an inhibitor of RBL-1 cell 5-LO with an IC50 value of 26 µM....
Biology Products: